A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
Abstract Little is known about the comparative vascular safety of basal insulins (intermediate-acting human insulin [IAHI] or long-acting insulin analogue [LAIA]) in type 2 diabetes (T2D). This study sought to examine the vascular and hypoglycemic effects associated with IAHI versus LAIA in real-wor...
Guardado en:
Autores principales: | Chun-Ting Yang, Kuan-Ying Li, Chen-Yi Yang, Huang-Tz Ou, Shihchen Kuo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/beb20b4d5d6d4f26815d08506cbc2896 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Insulin degludec is a new ultra-long-acting insulin analogue
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014) -
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
por: Wang F, et al.
Publicado: (2012) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014) -
Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2015) -
Use of short-acting insulin aspart in managing older people with diabetes
por: Eltayeb Marouf, et al.
Publicado: (2009)